Fig. 6

IGF2BP2 enhances colorectal cancer tumor growth in vivo. (A, B) HCT-116 cells stably expressing shNC, shIGF2BP2 were subcutaneously injected into the right side of nude mice. Tumor images were obtained using the PerkinElmer IVIS preclinical in vivo imaging system at 25 (A) and 28 (B) days after injection. (C) Tumor volumes were measured after every 3–4 days starting on the 7th day after injection. (D) The weight of the xenografted tumors was measured. (E) Tumor sections were subjected to IHC staining with an antibody against Ki-67. Scale bar: 50 μm. (F) Tumor sections were subjected to IHC staining with an antibody against TFRC. Scale bar: 50 μm. (G) Kaplan-Meier survival curve shows the overall survival rate of mice in each group (n = 5, *p < 0.05, using the log-rank test). (H) A proposed regulatory model depicting the role of IGF2BP2 in iron metabolism and tumorigenesis (By Figdraw). Each value represents the mean ± SD for triplicate samples (Student’s t-test). **P < 0.01 and **** P < 0.0001